EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer

Aaron C Tan iD, Gillianne G Y Lai, Stephanie P L Saw, Kevin L M Chua, Angela Takano, Boon-Hean Ong, Tina P T Koh, Amit Jain, Wan Ling Tan, Quan Sing Ng, Ravindran Kanesvaran, Tanujaa Rajasekaran und 12 weitere

Cancer · 15.05.2024 · 130 (10) · 1758-1765

DOI: 10.1002/cncr.35263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 29.02.2024. Verfasst von Aaron C Tan und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Lung Neoplasms, Circulating Tumor DNA, Neoplasm Recurrence, Local, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: International Association for the Study of Lung Cancer, National Medical Research Council, Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In early‐stage non–small cell lung cancer (NSCLC), recurrence is frequently observed. Circulating tumor DNA (ctDNA) has emerged as a noninvasive tool to risk stratify patients for recurrence after curative intent therapy. This study aimed to risk stratify patients with early‐stage NSCLC via a personalized, tumor‐informed multiplex polymerase chain reaction (mPCR) next‐generation sequencing assay.

Methods

This retrospective cohort study included patients with stage I–III NSCLC. Recruited patients received standard‐of‐care management (surgical resection with or without adjuvant chemotherapy, followed by surveillance). Whole‐exome sequencing of NSCLC resected tissue and matched germline DNA was used to design patient‐specific mPCR assays (Signatera, Natera, Inc) to track up to 16 single‐nucleotide variants in plasma samples.

Results

The overall cohort with analyzed plasma samples consisted of 57 patients. Stage distribution was 68% for stage I and 16% each for stages II and III. Presurgery (i.e., at baseline), ctDNA was detected in 15 of 57 patients (26%). ctDNA detection presurgery was significantly associated with shorter recurrence‐free survival (RFS; hazard ratio [HR], 3.54; 95% confidence interval [CI], 1.00–12.62; p = .009). In the postsurgery setting, ctDNA was detected in seven patients, of whom 100% experienced radiological recurrence. ctDNA positivity preceded radiological findings by a median lead time of 2.8 months (range, 0–12.9 months). Longitudinally, ctDNA detection at any time point was associated with shorter RFS (HR, 16.1; 95% CI, 1.63–158.9; p < .0001). Conclusions ctDNA detection before surgical resection was strongly associated with a high risk of relapse in early‐stage NSCLC in a large unique Asian cohort. Prospective studies are needed to assess the clinical utility of ctDNA status in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCirculating Tumor DNANeoplasm Recurrence, LocalCarcinoma, Non-Small-Cell LungHigh-Throughput Nucleotide SequencingNeoplasm, ResidualNeoplasm StagingHumansMaleFemaleMiddle AgedAgedRetrospective StudiesEarly Detection of CancerBiomarkers, TumorAdultAged, 80 and overMultiplex Polymerase Chain Reaction

Stichwörter der Autor:innen

circulating tumor DNAearly‐stage lung cancerliquid biopsynon–small cell lung cancer

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Division of Pathology, Singapore General Hospital, Singapore, Singapore.
  • Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore.
  • Natera, Inc, San Carlos, California, USA.

ORCID-Profile: Aaron C Tan, Derrick Renner

Förderung

  • International Association for the Study of Lung Cancer
  • National Medical Research Council, Singapore

Zitieren

APA

Tan, A. C., Lai, G. G. Y., Saw, S. P. L., Chua, K. L. M., Takano, A., Ong, B. H., Koh, T. P. T., Jain, A., Tan, W. L., Ng, Q. S., Kanesvaran, R., Rajasekaran, T., Kalashnikova, E., Renner, D., Sudhaman, S., Malhotra, M., Sethi, H., Liu, M. C., Aleshin, A., …, & Tan, D. S. W. (2024). Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer. Cancer, 130(10), 1758-1765. https://doi.org/10.1002/cncr.35263

Vancouver

Tan AC, Lai GGY, Saw SPL, Chua KLM, Takano A, Ong BH, et al. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer. Cancer. 2024;130(10):1758-1765. doi:10.1002/cncr.35263

BibTeX
@article{Tan2024,
  author = {Tan, Aaron C and Lai, Gillianne G Y and Saw, Stephanie P L and Chua, Kevin L M and Takano, Angela and Ong, Boon-Hean and Koh, Tina P T and Jain, Amit and Tan, Wan Ling and Ng, Quan Sing and Kanesvaran, Ravindran and Rajasekaran, Tanujaa and Kalashnikova, Ekaterina and Renner, Derrick and Sudhaman, Sumedha and Malhotra, Meenakshi and Sethi, Himanshu and Liu, Minetta C and Aleshin, Alexey and Lim, Wan-Teck and Tan, Eng-Huat and Skanderup, Anders J and Ang, Mei-Kim and Tan, Daniel S W},
  title = {Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {10},
  pages = {1758--1765},
  doi = {10.1002/cncr.35263}
}
Kostenlos starten →